15 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
and states on innovate payment mechanisms for high-cost cell and gene therapies. While Medicaid is not a significant driver of cell therapy sales
6-K
EX-1
AUTL
Autolus Therapeutics plc
30 Jun 21
Annual Report and Accounts
6:05am
and states on innovate payment mechanisms for high-cost cell and gene therapies. While Medicaid is not a significant driver of cell therapy sales
424B4
AUTL
Autolus Therapeutics plc
11 Apr 19
Prospectus supplement with pricing info
4:10pm
, or PRIME, designation from the European Medicines Agency, or EMA.
Continue to innovate and develop our product pipeline using a modular approach to T cell
F-1
3x9yb98ywlld5
8 Apr 19
Registration statement (foreign)
4:34pm
6-K
EX-1
3hsxcvl2 7irk9u7j7b0
15 Mar 19
Annual Report and Accounts
5:26pm
6-K
EX-99.1
cuo j66nynyr89xdx6s
25 Feb 19
Current report (foreign)
4:39pm
20-F
y4j9kdv uc4pzn7po7
23 Nov 18
Annual report (foreign)
12:00am
DRS
mrxjehv7e9 plw1iv
23 Nov 18
Draft registration statement
12:00am
424B4
d5i2k964oilbq0r
22 Jun 18
Prospectus supplement with pricing info
4:02pm
F-1/A
e7rz0j0cuowqe7 ca
19 Jun 18
Registration statement (foreign) (amended)
8:05am
F-1/A
rpmwl lr9ybe4
8 Jun 18
Registration statement (foreign) (amended)
6:25am
F-1/A
sm3hgfp
10 May 18
Registration statement (foreign) (amended)
5:19pm
F-1
ymh eeyd0
7 May 18
Registration statement (foreign)
4:45pm
- Prev
- 1
- Next